Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy
iTeos Therapeutics has announced that it has “deprioritised” inupadenant for the treatment of non-small cell lung cancer (NSCLC), following disappointing …
Post
-
-
New study highlights increasing incidence of late-onset multiple sclerosis in Italy
Multiple sclerosis (MS) is a chronic disease of the central nervous system that occurs when the immune system attacks the …
-
DREAM-HF trial sheds positive light on Revascor for ischemic HF
Mesoblast Limited recently announced positive Phase III trial results in the European Journal of Heart Failure. The use of Revascor …
-
FDA clears SpliceBio’s IND application to begin Stargardt disease therapy trial
The US Food and Drug Administration (FDA) has granted clearance to SpliceBio’s investigational new drug (IND) application to begin the …
-
Repare Therapeutics eyes Phase III cancer study after Mythic trial success
US-Canadian clinical-stage precision oncology company, Repare Therapeutics, has unveiled positive data from its Phase I gynecologic expansion trial evaluating Lunre+Camo, …
-
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients …
-
Trevi’s chronic cough trial in IPF subjects continues without sample size change
Trevi Therapeutics has announced that its Phase IIb CORAL trial of Haduvio in treating idiopathic pulmonary fibrosis (IPF) subjects with …
-
SK bioscience gains approval in Australia to begin trials of mRNA-based vaccine
SK bioscience has gained Australia’s Human Research Ethics Committee (HREC) approval to begin Phase I/II clinical trials of GBP560, an …
-
WHO trial guidance goes beyond race and gender when tackling diversity
Diversity has been a huge buzzword in the clinical trial space in the past few years. There has been a …
-
Highest risk CLL patients may benefit from CAR T with BTK inhibitor
Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi (lisocabtagene maraleucel) …
-
Blue Lake Biotechnology sees success in early RSV vaccine results
US-based clinical-stage intranasal vaccine company, Blue Lake Biotechnology’s pediatric nasal vaccine for respiratory syncytial virus (RSV), BLB201, was safe and …
-
Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial
Enlivex Therapeutics has gained approval from the Israeli Ministry of Health to commence a Phase I trial of Allocetra in …
-
Building up the infrastructure for future pandemic preparedness: Frontiers in rapid raw material production
With the world facing threats from new and emerging infectious diseases, the ability to rapidly ramp up production of essential …
-
‘Major milestone’ for UK clinical trials as new framework laid in parliament
New legislation is being laid in the UK Parliament today (12 December) that will change the regulatory framework for clinical …
-
Lilly’s Phase III SERD breast cancer study has success in certain patients
Healthcare giant Eli Lilly’s Phase III EMBER-3 study in patients with advanced breast cancer showed imlunestrant, cut the risk of …
